Humacyte, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-28. Between them they name 1 person. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Scott Coward
On September 22, 2026, the Board of Directors (the "Board") of Humacyte, Inc. (the "Company"), appointed Scott Coward and Paul Kuznik to the Board.
Find people with the same kind of experience as the senior executive at Humacyte, Inc., with the record behind each one.
Find candidates like senior executive at Humacyte, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Humacyte, Inc. is in the news or changes leadership.
Get an alert when Humacyte, Inc. changes leadershipWant the whole picture on Humacyte, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Humacyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Humacyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Tools for this story
Each opens in a new tab, filled in for Humacyte, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.